Key Takeaways
- Strong quarter, guidance held: Consolidated revenue grew 23% YoY with US up 42%, and full-year constant-currency growth guidance was maintained at 15%.
- CDMO is the growth engine: CDMO revenue grew 31% YoY, driven by commercial supply of signed contracts and new manufacturing partnerships, and the pipeline quality is described as better than ever.
- Cenexi loss was planned, recovery promised: The EUR 6 million EBITDA loss was driven by a planned summer shutdown; management expects profitability to return from Q3 and full-year guidance of EUR 20 million at high single-digit margin remains on track.
- Capacity is now the binding constraint: Liquid vial utilization hit 92% and is heading to ~102%, forcing deferral of planned shutdowns and triggering a ₹1,000 crore brownfield expansion plus a new greenfield project.
- What to watch next quarter: Whether Cenexi profitability actually returns, the Saudi NUPCO tender outcome, and the capex quantum for the Vizag greenfield project.
CDMO & Complex Injectables Momentum
- CDMO as strategic anchor: The segment is growing faster than the base business and is described as the most important driver of long-term strategy, with commercial supply from previously signed contracts now converting into revenue.
- Pipeline quality improving: Management stated the CDMO opportunity pipeline is robust, with both quality and scale of opportunities better than ever, providing increasing visibility and confidence in the future growth trajectory.
- Microsphere contracts signed: Three royalty-based microsphere projects were secured during the quarter; one exhibit batch is complete and two more are in line, with revenue expected post 2029-2030.
- Respiratory manufacturing win: A manufacturing contract for respiratory products was also secured during the quarter, adding to the CDMO portfolio breadth.
- GLP-1 progress: One more GLP-1 project was signed recently with exhibit batches ongoing; some launches may occur in Q1 or Q2 of FY28, with milestone income and tech transfer fees booked in FY27.
- In-licensing pipeline active: A second long-acting injectable product was in-licensed from China in the past two quarters, a $2 billion product still under patent with a ~3-year commercial timeline; clinicals will be done by Gland and manufacturing will remain in China.
Srinivas Sadu: "The CDMO business continues to emerge as a key growth engine for Gland Pharma and remains one of the most important drivers of our long-term strategy."
US & Regulated Markets Performance
- US revenue surged 42% YoY: Growth was driven by contribution from recent launches, increasing volumes from existing products, and continued momentum in CDMO programs.
- Europe grew 23% YoY: Supported by increasing customer engagement, higher volumes from existing products, recent launches, and improving commercial traction across both CDMO and critical injectable business.
- Four US launches in the quarter: The company launched four products in the US market and filed 11 ANDAs while receiving 10 approvals, sustaining a healthy launch cadence.
- Methylprednisolone suspension approval: Received approval for a generic of Pfizer's Medrol, described as a large product, adding to the US portfolio.
- New launches contribution: New launches are expected to contribute approximately 6-7% of growth going forward, providing a recurring tailwind.
- ROW softness expected to reverse: Rest of world revenue was impacted by market-specific supply and tender-related dynamics, especially the delay of NUPCO tender results from Saudi Arabia; management expects ROW to improve in H2.
- Saudi tender participation: 13 products were submitted for the NUPCO tender; management is confident on several products and expects the tender to open this quarter.
Cenexi Turnaround & Profitability Path
- Q2 loss was planned: The EUR 6 million EBITDA loss and lower revenue at Cenexi were primarily due to planned annual summer shutdown activities; the underlying operating trend remains encouraging.
- Full-year guidance intact: Management confirmed the previous guidance of EUR 20 crore EBITDA at high single-digit margin for FY2027 remains on track, with profitability expected to return from Q3 onwards.
- Strategy prioritizes profit over growth: Cenexi's focus is on making operations more efficient and profitable rather than top-line growth; minimum revenue growth is expected while the rest of the business grows faster.
- Cost reduction plan: The plan involves reducing headcount and investing in faster lines for operational efficiencies, though the transition will involve some shutdown periods as new lines are installed.
- Investments on track: Planned investments including a new vial and lyophilization block at BLA and a high-speed ampoule line at Fontenay remain on track, expected to strengthen the platform's competitiveness.
- Tax rate normalization expected: The elevated effective tax rate of ~33% in Q2 was largely attributable to Cenexi losses during the shutdown, since those losses are not eligible for tax benefits; normalization is expected as Cenexi returns to profitability from Q3.
Srinivas Sadu: "Cenexi, like earlier said, the growth, the focus is on making it more efficient and make profitable rather than the top line. There will be minimum growth from revenue perspective, but the idea is to make it more profitable."
Capacity Expansion & Capex
- Capacity constraints are acute: Liquid vial utilization is at 92% and expected to hit approximately 102% next year; ophthalmic, bags, and liquid vials are all struggling for capacity, and planned shutdowns on some lines are being deferred because no spare capacity exists to absorb the downtime.
- Brownfield expansion at Pashamylaram: Board approved a ₹1,000 crore brownfield block with three isolator-based vial manufacturing lines; commercial operations are anticipated to commence from FY2030, with a two-year completion timeline to meet demand from signed contracts.
- Greenfield project at Vizag SEZ: Land has been acquired and project planning is underway; full capex quantum will be presented for Board approval next quarter, with a four-year phased build program.
- Bag line awaiting FDA inspection: Additional bag manufacturing capacity has been installed during the year and is awaiting US FDA inspection; commercialization post-inspection will de-bottleneck capacity constraints for product supplies.
- Capex philosophy: The ₹3,000 crore investment program is backed by contracts in place or at minimum forecasts; the greenfield project is driven by the broader business environment and capacity running out, and will be built in phases.
Srinivas Sadu: "We actually, we're supposed to take shutdowns a couple of lines, but we're not taking because we don't have capacity to fill if we take shutdown. So that's the situation we are in."
Margins, R&D & Financial Health
- EBITDA margin improved to 26%: Up from approximately 21% YoY, supported by stronger revenue, increasing CDMO contribution, favorable business mix, operating leverage, and ongoing efficiency initiatives, despite significantly higher R&D investment.
- Gross margin stable YoY at 63%: Productivity improvements, manufacturing optimization, alternate sourcing, and yield enhancement initiatives offset headwinds; the sequential decline from 65% to 63.5% was driven by Cenexi's lower revenue during the shutdown, since Cenexi carries higher gross margins.
- R&D spend stepped up: Expenditure increased to ₹107.7 crore (6% of revenue) from ₹77.2 crore in the previous quarter, focused on complex injectables including suspensions, peptides, hormones, and ophthalmic solutions; a slight increase is expected over time due to product complexity, but margin levels will be maintained.
- Working capital improved: Working capital days improved to 158 days driven primarily by inventory optimization initiatives and enhanced inventory management practices.
- Other income declined sequentially: The reduction versus Q1 FY27 was largely due to a change in FX gain/loss.
Regulatory, Leadership & Strategic Updates
- Two successful FDA inspections: The Vizag oncology facility completed a US FDA inspection with zero observations; the Dundigal facility underwent inspection in October and concluded with four procedural observations, with neither data integrity observations nor repeat observations.
- New CEO joining: Mr. Deepak Sapra will join as CEO on November 16th, filling a key leadership position.
- Cenexi President onboarded: Mr. Ajay Sahni joined earlier in the week of the call as President of Cenexi operations, strengthening local leadership for the turnaround.
- Senior hires across functions: New heads of tech transfer, strategy and innovative medicines (India), and business development (China) were onboarded, along with two senior project management hires; a Chief Investment Officer based in China will also join, with a global role covering acquisitions including US biologics and in-licensing complex products from China.
- US biologics acquisition approach: Management will not pursue loss-making or very low EBITDA assets, preferring profitable assets even at a higher price; focus is on contracts commercializing in year two and quality of the management team, with a stated preference for US over European plants.
- India market entry via innovation: The company plans to enter the Indian market with innovative in-licensed products rather than generics, leveraging Fosun subsidiaries and other partners, with lower investment required for India-only rights.
Srinivas Sadu: "One thing is probably not be looking at a loss-making or a very low EBITDA asset. Even if you have to pay a little higher, but we will go with a profitable asset."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue growth | 15% on constant currency basis | FY27 |
| Cenexi profitability | EUR 20 crore at high single-digit EBITDA margin | FY27 (guidance confirmed as still on track) |
| Cenexi profitability return | Profitability to return from Q3 onwards | Q3 FY27 |
| Tax rate normalization | Normalization of overall effective tax rate as Cenexi returns to profitability | From Q3 FY27 |
| ROW market improvement | ROW market expected to improve in H2 | H2 FY27 |
| Saudi NUPCO tender | 13 products participated; tender opening expected this quarter | Q3 FY27 |
| Pashamylaram brownfield | Three isolator-based vial lines; ~₹1,000 crore capex; commercial operations commence | FY2030 |
| Vizag SEZ greenfield | Board approval for additional capex to be sought | Next quarter (Q3 FY27) |
| Bag line commercialization | Post US FDA inspection, de-bottleneck capacity | Undated (inspection awaited) |
| Second in-licensed long-acting injectable | Clinicals by Gland; manufacturing in China; commercial launch | ~3 years |
| Microsphere contracts | Three projects; revenue expected post 2029-2030 | Post 2029-2030 |
| GLP-1 launches | Some launches possible; milestone income and tech transfer fees in FY27 | Q1/Q2 FY28 (next year) |
| R&D spend trajectory | Slight increase over time; margin levels will be maintained | Ongoing |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹1,833.6 cr, +23% YoY |
| EBITDA | ₹480.4 cr, +53% YoY |
| Adjusted EBITDA | ₹503 cr, margin 27% |
| Profit after tax | ₹290.8 cr, +58% YoY |
| Gross margin | 63%, vs 65% in Q1 FY27; H1 FY27 at 64%, flat YoY |
| R&D spend | ₹107.7 cr, 6% of revenue, vs ₹77.2 cr in Q1 FY27 |
| CDMO revenue | ₹822.7 cr, +31% YoY, ~45% of total revenue |
| Critical injectables revenue | ₹1,010.9 cr, +18% YoY |
| US revenue | ₹1,179.5 cr, +42% YoY |
| Europe and other regulated markets revenue | ₹411 cr, +23% YoY |
| Rest of world revenue | ₹204.4 cr, impacted by NUPCO tender delay |
| Cenexi revenue | EUR 41 million, vs EUR 40 million in Q2 FY26 |
| Cenexi EBITDA | negative EUR 6 million, due to planned annual summer shutdowns |
| Cash and cash equivalents | ₹3,441.2 cr as of Sep 30, 2026 |
| Net cash position | ₹3,221.6 cr as of Sep 30, 2026 |
| Working capital days | 158 days, improved driven by inventory optimization |
| ANDAs filed | 11 filed, 10 approvals received, 4 products launched in the US |
| Full-year revenue growth guidance | 15% on constant currency basis, reiterated |
| Liquid vials capacity utilization | 92%, anticipated to reach close to 102% next year |
| Brownfield capex at Pashamylaram | ~₹1,000 cr, three isolator-based vial lines, commercial ops from FY2030 |
| Total capex excluding greenfield | ~₹3,000 cr, adding 300–400 crore units of capacity |
| Total capex including greenfield | ~₹5,000 cr over next four years (per an analyst's math, which management did not confirm) |